225Ac and 223Ra production via 800MeV proton irradiation of natural thorium targets

Weidner, John W.; Mashnik, S. G.; John, Kevin D.; Ballard, B.; Birnbaum, Eva R.; Bitteker, Leo; Couture, A.; Fassbender, Michael E.; Goff, George S.; Gritzo, R.; Hemez, François M.; Runde, Wolfgang; Ullmann, J. L.; Wolfsberg, Laura E.; Nortier, F.M.

doi:10.1016/j.apradiso.2012.07.003

Cited by 64 publications

(34 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the majority of the approximately 63 GBq global annual 225 Ac supply is derived from the decay of 229 Th (t 1/2 = 7600 y) through the 225 Ac parent isotope 225 Ra (t 1/2 = 14.9 d) [14][15][16][17][18][19], these 229 Th sources remain fixed. The resulting low annual 225 Ac availability has spurred many recent efforts to increase 225 Ac production via particle accelerators-most notably those of the US Department of Energy's Isotope Program [16,[20][21][22][23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Design of a Thorium Metal Target for 225Ac Production at TRIUMF

et al. 2019

View full text Add to dashboard Cite

With recent impressive clinical results of targeted alpha therapy using 225Ac, significant effort has been directed towards providing a reliable and sufficient supply of 225Ac to enable widespread using of 225Ac-radiopharmaceuticals. TRIUMF has begun production of 225Ac via spallation of thorium metal with 480 MeV protons. As part of this program, a new 225Ac-production target system capable of withstanding the power deposited by the proton beam was designed and its performance simulated over a range of potential operating parameters. Special attention was given to heat transfer and stresses within the target components. The target was successfully tested in two irradiations with a 72–73 µA proton beam for a duration of 36.5 h. The decay corrected activity at end of irradiation (average ± standard deviation) was (524 ± 21) MBq (14.2 mCi) and (86 ± 13) MBq (2.3 mCi) for 225Ac and 225Ra, respectively. These correspond to saturation yields of 72.5 MBq/µA for 225Ac and 17.6 MBq/µA for 225Ra. Longer irradiations and production scale-up are planned in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Design of a Thorium Metal Target for 225Ac Production at TRIUMF

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Despite the promising preliminary results obtained with 213 Bi-DOTATOC and 213 Bisubstance P in patients, the short half-life of 213 Bi (45.6 min) and the costs and limited availability of 225 Ac/ 213 Bi generators limit clinical use. The recently described accelerator-driven production of 225 Ac may allow it to be produced in quantities sufficient to supply centers for clinical trials and make the treatment available to a wider range of centers (21).…”

Section: Introduction Of Powerful A-emittersmentioning

confidence: 99%

Radiopeptides for Imaging and Therapy: A Radiant Future

2015

View full text Add to dashboard Cite

show abstract

“…227 Ac activation/decay sequence [2]. Proton fission of 232 Th as an alternative to the reactor production method appeared quite recently [3,4]. A natural source of 227 Ac, originating from the decay chain of 235 U, is also available in limited quantities.…”

Section: Introductionmentioning

confidence: 99%